Judge Rules Bristol Myers Must Face $6.7B Lawsuit Over Delayed Cancer Drug

A U.S. judge on Monday rejected Bristol Myers Squibb’s bid to dismiss a $6.7 billion lawsuit claiming it cheated shareholders of the former Celgene by delaying federal approval for three drugs, including the cancer treatment Breyanzi, by specified deadlines. While …

Read the full article →

Share:

More Posts

Send Us A Message